Preparation and evaluation of Maltodextrin based Proniosomes containing Capecitabine
DOI:
https://doi.org/10.21276/IJRDPL.2278-0238.2017.6(7).2856-2861Keywords:
Capecitabine, Proniosome, Maltodextrin, Span 80, Span 20Abstract
Maltodextrin based capecitabine proniosomes were fabricated by conventional slurry method with different surfactant: cholesterol molar ratio keeping constant capecitabine and dicetyl phosphate concentration. The fabricated proniosomes were evaluated for FTIR and flow properties. Further proniosomes were hydrated to get desired niosomes and the obtained niosomes were subjected for various evaluation parameters such as entrapment efficiency, in vitro drug release and stability studies as per ICH guidelines. The entrapment efficiency followed the trend, span 80 (C18)> span 20 (C12) as increasing the alkyl chain lengths are leading to higher entrapment efficiency. The in vitro data suggest biphasic drug release, initial burst followed steady state. In all the case, best-fit model was found to be matrix with Peppas exponential value was greater than 0.5 indicating drug released by non Fickian (anomalous) mechanism. The result of investigation demonstrated that proniosomes offers an alternate drug carrier with targeted specificity.
Downloads
References
Mangit C, Kawakami S, Nishikawa M, Hashida M. Targeted and sustained drug delivery using PEGlyatedgalactosylated liposomes. Int J Pharm 2003; 266: 77-84.
Vyas SP, Singh RP, Jain S, Mishra V, Mahor S, Singh P. Nonionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int J Pharm 2005; 296: 80-86.
Dufes C, Gaillard F, Uchegbu IF, Schatzlein AG, Olievier JC, Muller JM. Glucose-targeted niosomes deliver vaso active intestinal peptide to the brain. Int J Pharm 2004; 285: 77-85.
Azmin MN, Florence AT, Handjani-vila RM, Stewert JF, Vanlerberghe G. The effect of nonionic surfactant vesicle entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol 1985; 37: 237-242.
Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and Properties of niosome nonionic surfactant vesicles. J Pharm Pharmacol 1985; 37: 863- 868.
Rhodes DG, Chengjiu H. Proniosomes A Novel Drug Carrier Preparation. Int J Pharm 1999; 185, 23-35.
Almira I, Blazek W, Rhodes DG. Maltodextrin-Based Proniosomes. AAPS PharmSciTech 2001; 3(1): E1.
Almira I, Blazek W, Rhodes DG, SEM Imaging Predicts Quality of Niosomes from Maltodextrin-Based Proniosomes. Pharmaceutical Research 2001; 18(5): 656-661.
Goodman and Gilman. The pharmacological basis of therapeutics. 10th International edition; 1404-1405.
Hirsch BR, Zafar SY. Capecitabine in the management of colorectal cancer. Cancer Manag Res 2011; 3:79-89.
Walko CM, Lindley C. Capecitabine: a review. ClinTher 2005; 27:23-44.
Varshosaz J, Pardakhty A, Baharanchi SM. Sorbitonmonopalmitate based proniosomes for transdermal delivery of chlorpheniramine maleate. Drug Delivery 2005; 12(2): 75-82.
Solanki AB, Parikh JR, Parikh RH, Formulation and Optimization of Piroxicam Proniosomes by 3-Factor, 3-Level Box-Behnken Design. AAPS PharmSciTech2007; 8(4): E1- E7.
Liberman H, Lachman L, Schwartz J. Pharmaceutical dosage forms: Tablets, Vol II. 2nd Ed, New York: Marcel Dekker Inc.1990: 229.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
.